Background: Ureaplasma urealyticum and Mycoplasma hominis are associated with an increased risk of pregnancy complications, such as preterm birth and premature membrane rupture. The purpose of this study was to determine the isolation rates and antimicrobial susceptibilities of genital mycoplasma in a sample of pregnant women from Jinju, Korea. Methods: Vaginal swabs were obtained from 258 pregnant women between 2004 and 2008 and tested for the presence of U. urealyticum and M. hominis at Gyeongsang National University Hospital. The identification and antimicrobial susceptibilities of U. urealyticum and M. hominis were determined with a commercially available kit, the Mycoplasma IST2 Kit (bioMerieux, Marcy-l'Etoile, France), and evaluated according to standards set by the Clinical and Laboratory Standards Institute (CLSI). Results: U. urealyticum only was detected in 105 specimens (38.6%), while M. hominis only was detected only in 2 specimens (1.8%). Seven specimens (6.7%) were positive both for U. urealyticum and M.
INTRODUCTION
Ureaplasma urealyticum and Mycoplasma hominis are commensals which can be detected in the lower genitourinary tract of sexually active women, resulting in colonization of genitalia by sexual contact [1, 2] . Although most colonized women remain asymptomatic, vaginal colonization with U. urealyticum and M. hominis are associated with an increased risk of developing certain pathogenic conditions and pregnancy complications, such as bacterial vaginosis, pelvic inflammatory disease, postpartum fever, postpartum septicemia, infertility, premature rupture of the membranes, preterm labor, preterm birth, and systemic neonatal infections [2] [3] [4] [5] . Such aggravating conditions require the therapeutic use of antimicrobials. Tetracyclines and quinolones are the drugs of choice [6] [7] [8] , but obstetricians empirically use macrolides for treatment of pregnant women in many cases [9] . The antimicrobial susceptibility of genital mycoplasmas has changed over time and is different by geographic area [1, [10] [11] [12] [13] [14] [15] . It is important to know the antimicrobial susceptibilities of genital mycoplasmas in a specific geographic region for the successful treatment. No such a study regarding the antimicrobial susceptibilities of U. urealyticum and M. hominis has been reported in Korea so far. The present study was performed to investigate the isolation rates and the antimicrobial susceptibilities of U. urealyticum and M. hominis in pregnant women who reside in Jinju, a southern area of Korea. determined with a commercially available Mycoplasma IST2 kit (bioMerieux, Macrcy-l'Etoile, France), as indicated by the manufacturer. Briefly, the cotton swab included in the kit was inoculated in R1 transport medium, which inhibits most Gram-negative and -positive bacteria. The inoculated R1 medium was vortexed rapidly and 3 mL was added to the growth R2 medium, which contained 1 mL of lyophilized urea/arginine broth. After reconstitution and shaking, 55μL was dispensed into each of the 22 test wells on the strip. Two drops of mineral oil were added to each well. The remainder of the R2 medium and the inoculated strip were then incubated at 37 o C and observed for color changes at 24 and 48 h. The antimicrobial susceptibility testing included tetracycline, doxycycline, erythromycin, azithromycin, clarithromycin, josamycin, ofloxacin, ciprofloxacin, and pristinamycin. The development or absence of red color on the relevant part of the strip provided an index of resistance or susceptibility to each antimicrobial agent, respectively, according to the guidelines of the CLSI. The breakpoints for the antimicrobials tested are given in Table 1 .
MATERIALS AND METHODS

RESULTS
U. urealyticum and M. hominis were detected in 114 of 258 cultures (44.2%). U. urealyticum was detected in 105 cultures (38.6%) and M. hominis was detected in 2 cultures (1.8%). Seven cultures (6.7%) were positive both for U. urealyticum and M. hominis. The susceptibilities of U. urealyticum to azithromycin, erythromycin, and clarithromycin were 75.2%, 82.9%, and 88.6%, respectively, while nearly all of the strains were susceptible to josamycin (99.0%) and pristinamycin (100%). The susceptibilities of ofloxacin and ciprofloxacin were shown to be 56.2% and 15.2% against U. urealyticum. Two strains of M. hominis were susceptible to doxycycline, josamycin, and pristinamycin, while resistant to azithromycin, erythromycin, and clarithromycin. The antimicrobial susceptibility pattern of the mixed strains was similar to that of M. hominis (Table 1) .
DISCUSSION
Genital mycoplasmas have been detected more frequently in the group with preterm deliveries compared to the women who deliver at term. The presence of mycoplasma in the lower genital tract early in pregnancy is known as a risk factor for preterm delivery. Among the pregnant women with premature labor, the duration of pregnancy was prolonged after the onset of premature labor in the M. hominis-positive group than that in M. hominis-negative group [16] . Early pregnancy screening for genital mycoplasmas and following treatment may reduce preterm deliveries [16, 17] . In the present study, the isolation rate of U. urealyticum and M. hominis in pregnant women was 44.2% and our findings are similar to that of other reports, with a higher rate of U. ureaplasma colonization (38.6%) and a lower rate of M. hominis (1.8%) [18] [19] [20] . However, it is difficult to regard all isolates of U. urealyticum and M. hominis as pathogens or risk factors of preterm delivery because we did not compare the preterm labor group with the term group. We did not review the clinical outcomes after the tests.
There are a limited number of drugs available against genital mycoplasmas in pregnant women. Agents like β-lactams are completely inactive against U. urealyticum and M. hominis due to the lack of a cell wall. The antimicrobial susceptibilities to macrolides, which are empirical treatment regimen for genital mycoplasma infection, were different between the two species [21] [22] [23] [24] . With respect to antimicrobial susceptibilities of genital mycoplasmas, the U. urealyticum strains were susceptible to tetracycline and doxycycline (81.0% and 88.6%, respectively). M. hominis strains (N=2) were susceptible to tetracycline and doxycycline (50% and 100%, respectively). Among the macrolides, the highest susceptibility against U. urealyticum was observed by josamycin (99.0%), followed by clarithromycin (88.6%), and erythromycin (82.9%), while the susecptibility to azithromycin, which is most commonly used antimicrobial for pregnant women in our region, was not as high (75.2%) as the other macrolides. M. hominis strains are known to be naturally resistant to C14 macrolides (erythromycin, clarithromycin, and roxithromycin) [8, [21] [22] [23] [24] , which is fully in agreement with our results. M. hominis was resistant to three types of the macrolides tested, except josamycin. All strains of U. urealyticum and M. hominis were completely susceptible to pristinamycin. Ofloxacin and ciprofloxacin proved to be ineffective against the majority of strains of U. urealyticum and M. hominis and a significant number of U. urealyticum strains were intermediately susceptible (39% for ofloxacin and 62.8% for ciprofloxacin). The pattern of antimicrobial susceptibilities against mixed isolates (U. urealyticum and M. hominis) was similar to that of M. hominis. U. urealyticum strains isolated from the women with cervicitis in Athens, Greece were highly susceptible to tetracycline, doxycycline, and pristinamycin, while erythromycin, azithromycin, clarithromycin, ciprofloxacin, and ofloxacin were inactive against most of the strains. M. hominis strains were completely susceptible to tetracycline, doxycycline, and pristinamycin [18] . The susceptibilities of macrolides against U. urealyticum strains in Greece were much lower (14.4∼79.2%) than our results (75.2∼99%). Susceptibilities of erythromycin and ofloxacin against U. urealyticum strains were only 10.3% and 11.4%, respectively in Bolu, Turkey [19] . However, doxycycline or ofloxacin was used as a first choice in the empirical treatment of U. urealyticum and M. hominis infections in Japan [1] ; we observed that erythromycin was still active, but quinolone derivatives (ofloxacin and ciprofloxacin) were inactive against U. urealyticum and M. hominis in our region. These discrepancies might be due to the different antimicrobial-use policies, which lead to the emergence of resistance to one or another antimicrobial agents. The empirical treatment can be ineffective for these reasons. Thus, it is difficult to establish common guidelines for the empirical treatment of genital mycoplasma infections. In the present study, we determined the antimicrobial susceptibilities for genital mycoplasma in Jinju, which represents a specific geographic region, rather than whole country. A nationwide survey may enable us to establish new guidelines for the treatment of genital mycoplasma infections in Korea.
In conclusion, the isolation rate of genital mycoplasma in pregnant women was 44.2% in Jinju. Both isolates were resistant to quinolones, but susceptible to josamycin and doxycyline. Characteristically, susceptibility of azithromycin, the empirical treatment regimen for pregnant women in our geographic region, was not as high as we expected. All of the mixed isolates were resistant to azithromycin. Therefore, empirical treatment without the isolation and identification of genital mycoplasma would fail in many cases. In vitro determination of the antimicrobial susceptibility of the genital mycoplasma in each clinical case is required to avoid therapeutic failures. 
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